Prices delayed by at least 15 minutes | Print


E-Therapeutics PLC (ETX)

ORD 0.1P
Sell: 10.5p|Buy: 11p|Change: 0.15 (-1.35%)

Open 

11.3p


Previous close 

11.15p


Trade high 

11.45p


Volume 

131,822


Year high 

24.00p


Year low 

8.00p


Dividend yield 

-


Market capitalisation 

£64.28 mn


P/E ratio 

-


ISIN 

GB00B2823H99


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
E-Therapeutics PLC- 4.90
FTSE AIM All Share+ 0.35
More...

Company profile

e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202411:12:521190.99
28/03/202411:12:521180.88
28/03/202411:08:421188397.13
28/03/202411:08:421110,0001,100.00
28/03/202411:08:321120,0002,200.00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.